Last updated: February 13, 2026
What is NDC 00004-0800?
NDC 00004-0800 refers to a specific drug product listed in the National Drug Code registry. It corresponds to Erythropoietin Alpha (Epoetin alfa) injection, USP, sold under brand names like Epogen or Procrit. This drug is used to treat anemia, especially in chronic kidney disease, chemotherapy, or post-transplant settings.
Market Overview
Market size and growth:
The global erythropoietin market was valued at approximately USD 12 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, driven by increasing prevalence of anemia associated with chronic kidney disease and cancer treatments.
Key players:
- Amgen (Epogen, Aranesp)
- Roche (noted for Eporatio in some markets)
- Johnson & Johnson (Retacrit)
- Sinovac and other biosimilar producers
Market segments:
- Brand-name erythropoietins (Epogen, Procrit)
- Biosimilars (Retacrit, others)
Geographic distribution:
- North America accounts for 55% of sales, due to high CKD prevalence and advanced healthcare infrastructure.
- Europe contributes 25%.
- Asia-Pacific is emerging, with growth driven by increasing CKD diagnoses and biosimilar adoption.
Regulatory Environment:
Multiple regulators, including the FDA and EMA, have tightened oversight over erythropoietin products to address safety concerns like thromboembolic events and increased tumor progression risks. Biosimilar approvals are expanding, promoting price competition.
Price Analysis
Historical pricing trends:
- Brand-name formulations (e.g., Procrit, Epogen) have retail prices ranging from USD 200 to USD 400 per dose, depending on the dosage and procurement arrangements.
- Biosimilars: Prices are approximately 30-50% lower than original products, with some batches priced at USD 120-250 per dose.
Pricing drivers:
- Manufacturer list prices
- Reimbursement policies
- Contract negotiations with hospitals and payers
- Biosimilar adoption rates
Average wholesale prices (AWP):
- 2022: USD 350 per dose for originators
- 2023: USD 250-300 per dose for biosimilars
Price projections (2023-2030):
- Original erythropoietin products likely to experience gradual price declines due to biosimilar entry.
- Biosimilar prices expected to stabilize around 20-30% below originators’ prices, with potential discounts of up to 50% in certain markets.
Projected Price Ranges (per dose, USD):
| Year |
Brand-Name (origins) |
Biosimilars |
| 2023 |
250-300 |
130-200 |
| 2025 |
225-275 |
115-180 |
| 2030 |
200-250 |
100-150 |
Future Market Drivers
- Biosimilar penetration: As patents expire, biosimilar adoption accelerates, pressuring prices downward.
- Regulatory approvals: Expanded approval pathways for biosimilars, especially in emerging markets.
- Pricing and reimbursement policies: Governments seek cost savings, which could accelerate biosimilar uptake.
- Clinical safety updates: New data may influence prescribing patterns, impacting overall market size and pricing.
Risks and Challenges
- Regulatory hurdles: Stringent approval processes regulate biosimilar interchangeability.
- Market acceptance: Physicians may prefer established originator products, delaying biosimilar penetration.
- Pricing pressure: Increased biosimilar competition drives down prices and margins.
- Safety concerns: Post-market safety signals could restrict use or lead to pricing adjustments.
Key Takeaways
- The erythropoietin market is mature, with both originators and biosimilars sharing market share.
- Biosimilars will likely dominate growth, with prices dropping 20-50% over the next decade.
- Price declines for NDC 00004-0800 will be driven by increased biosimilar adoption and regulatory facilitation.
- Overall market growth continues, supported by rising CKD and cancer patient populations globally.
- Strategic positioning in biosimilar manufacturing or advanced therapeutics could prove advantageous.
FAQs
1. Will the price of NDC 00004-0800 decrease significantly in the next five years?
Yes, biosimilar entries are expected to reduce average prices by 20-50% due to competitive pressures.
2. Which regions will see the fastest price declines?
Emerging markets adopting biosimilars, particularly Asia-Pacific, will see the fastest and steepest price reductions.
3. How will regulatory changes affect price trends?
Easier approval pathways for biosimilars and increased interchangeability policies will boost adoption and drive prices downward.
4. What factors could limit biosimilar uptake?
Physician preference for originator products, safety concerns, and limited biosimilar reimbursement coverage could slow adoption.
5. Is the market for erythropoietin mature or expanding?
It is mature, with growth driven primarily by biosimilar competition and global demographic shifts toward chronic disease management.
References
- Grand View Research. Erythropoietin Market Size, Share & Trends Analysis Report, 2022.
- IQVIA. Global Biosimilar Market Statistics, 2023.
- U.S. FDA. Biosimilar Approval Database, 2023.
- MarketWatch. Biosimilar Competition in Erythropoietin, 2023.
- Centers for Disease Control and Prevention. Chronic Kidney Disease Statistics, 2022.
